Standard Operating Procedures (SOPs) are critical for the operation of any business, particularly in regulated industries like pharmaceuticals where precision, safety, and compliance with regulatory requirements are paramount. For a pharmaceutical company, SOPs for observational studies and clinical trials should be separated due to the distinct nature and objectives of each type of study. Here are the main reasons:
[1] Different objectives: Clinical trials are experiments designed to evaluate the safety and efficacy of a new drug or intervention. On the other hand, observational studies are non-interventional; they involve the collection of data without altering the patients’ usual treatment or environment, aiming to observe and analyse patterns, effects, or outcomes.
[2] Regulatory requirements: Clinical trials are highly regulated, with strict GxP requirements from bodies like the FDA or EMA. Observational studies, while still regulated, do not fall under the same stringent GxP requirements. Having separate SOPs ensures compliance with the correct set of regulations for each type of study.
[3] Study design and conduct: The design and conduct of clinical trials and observational studies are significantly different. For instance, clinical trials are generally randomized, controlled, and blinded studies. In contrast, observational studies may involve case-control studies, cohort studies, or cross-sectional studies. Different SOPs can specify the appropriate designs, methods and checks for data collection, storage, and analysis in each case.
[4] Patient consent and confidentiality: In clinical trials, patients provide informed consent for the specific interventional treatment they will receive. In observational studies, while consent is still required, it’s often related to access and use of their medical data rather than a specific treatment. Thus, separate SOPs can address these differing requirements.
[5] Risk Management: Risks and safety considerations also vary between clinical trials and observational studies. The risks of clinical trials often relate to the new drug or intervention being tested, while observational studies’ risks typically concern data protection and patient privacy.
[6] Reporting Results: Different types of studies may also have different reporting requirements, including timelines, formats, and recipients of the information (e.g., regulatory authorities, ethics committees, sponsors).
By having separate SOPs, companies ensure that all these aspects are appropriately addressed, leading to better quality, more ethical research, and improved compliance with regulatory requirements. It also helps in training and guiding staff effectively in their roles for different studies.
Share this story...
Real World Evidence (RWE) 101 – Ethical Imperatives (CIOMS 2023)
RWE 101 - Ethical Imperatives (CIOMS 2023) Informed decision making with patients typically relies on evidence from clinical trials that describe the likely benefits and toxicities. However, patients treated [...]
Real World Evidence (RWE) 101 – Ethical Imperatives
RWE 101 - Ethical Imperatives Real-world evidence (RWE) refers to the clinical evidence regarding the usage and potential benefits or risks of a product derived from analysis of real-world [...]
Real World Evidence (RWE) 101 – The Importance of Intent
RWE 101 - The Importance of Intent Real-world evidence (RWE) is the clinical evidence about the usage and potential benefits or risks of a product derived from the analysis [...]
Real World Evidence (RWE) 101 – Inspections
RWE 101 - Inspections Real-World Evidence (RWE) can include data from sources such as electronic health records (EHRs), insurance claims and billing activities, patient registries, patient-generated data, and data [...]
Real World Evidence (RWE) 101 – Audits
RWE 101 - Audits A quality assurance auditor in the context of a real-world evidence (RWE) study has several responsibilities, key among them ensuring that all facets of the [...]
Real World Evidence (RWE) 101 – Compliance Maps
RWE 101 - Compliance Maps In the context of multi-country Real-World Evidence (RWE) studies, "Regulatory Compliance Maps" are essentially a detailed representation of the diverse regulatory requirements specific to [...]







